Peptide Therapy

Advanced Regenerative Medicine

SERMORELIN

·       GHRH (1-29): Growth Hormone Releasing Hormone.

·       Stimulates the anterior pituitary to release endogenous growth hormone.

·       Increased hepatic production of insulin-like growth factor-1 (IGF-1)

·       Enhanced protein synthesis,

·       Increased lipolysis

·       Improved nitrogen retention

·       Support of tissue repair and collagen synthesis

EFFECTS

·       Improved lean body mass

·       Reduction in fat mass

·       Improved muscle preservation during weight loss

·       Improved exercise recovery

·       Enhanced connective tissue repair

·       May support wound healing

·       Improved sleep

·       Increased energy and exercise tolerance

·       May support collagen production improving skin thickness and elasticity

SIDE EFFECTS

  • Common: Injection site pain, headache, facial flushing, dizziness, nausea, fatigue

  • Uncommon: Fluid retention, arthralgia, increased appetite, tingling sensations

  • Serious Potential Risk: Excessive IFG-1, Worsening insulin resistance, carpal tunnel, worsening OSA, theoretical concern regarding stimulation of active malignancy through increased GH/IGF-1 signaling

  • Contraindications: Active malignancy, hypersensitivity, pregnancy, breastfeeding, significant pituitary disease, severe/untreated OSA

DOSING

  • Injection:  100-300 mcg SubQ at night two hours after last meal. 5-7 nights/week

  • Oral: 250-500 mcg at nights two hours after last meal. 5-7 nights/week

EVIDENCE

·       Thorner et al. 1995, Khorram et al. 1997, Parkash & Goa 1999